ADBiotech Co (179530) Fair Value & Analysis
Healthcare · KR · Market cap 35.9B KRW
Fair value as of: Jul 22, 2026
From 1 valuation models · updated 19 days ago
Share price −5.0% over the past month.
Below-average quality, and screening another 79% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (653.62 KRW). The favourable scenario is already priced in.
- Weak quality (24/100) and above fair value at the same time, the margin of safety is missing on both counts.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
- A fairly wide model range (326.81 KRW to 653.62 KRW) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 22, 2026.
How to read this chart
55‑month range 1,350 KRW – 9,240 KRW · fair‑value band 326.81 KRW – 653.62 KRW · the 2,110 KRW price screens above the 437.92 KRW fair value. Dashed = 300-day average. As of Jul 22, 2026.
Analysis
ADBiotech Co (179530) currently trades at 2,110 KRW, while our model-based Fair Value estimate is 437.92 KRW, implying the stock looks roughly 79.3% overvalued today. The Quality Score stands at 24/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Over the trailing twelve months, ADBiotech Co generated revenue of 12.5B KRW at a net margin of -66.6%. Revenue declined 11.1% year over year. It earns a return on equity of -80.2%. Net debt stands at 12.8B KRW. Fundamentals as of Jul 22, 2026
Our scenario range runs from 326.81 KRW (bear case) to 653.62 KRW (bull case); at 2,110 KRW, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 58% below its 52-week high and 62% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -43% fair-value upside, at -79%, 179530 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 1 models by family
Notify me when 179530 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 22, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 24 · Market factors (momentum, volatility) 31
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
ADBiotech Co., Ltd. develops and sells antibodies for livestock, fisheries, and humans in South Korea and internationally. The company offers antibiotic, disinfectant, helminthic, over the counter drugs, supplementary feed, and metabolic drugs. It also offers health functional and processed foods. ADBiotech Co., Ltd.
Full company description
ADBiotech Co., Ltd. develops and sells antibodies for livestock, fisheries, and humans in South Korea and internationally. The company offers antibiotic, disinfectant, helminthic, over the counter drugs, supplementary feed, and metabolic drugs. It also offers health functional and processed foods. ADBiotech Co., Ltd. was founded in 2000 and is based in Chuncheon-si, South Korea.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
ADBiotech Co reported revenue of 12.9B KRW in FY2025 versus 11.8B KRW in FY2021, a compound +2.2%/yr. Reported net income was −3.3B KRW in FY2025.
179530 screens 79% overvalued. Compare with Vertex Pharmaceuticals Incorporated →
Peer Group
Biotechnology · 601 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 22, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | $486.03 | $278.78 | -43% |
| Regeneron Pharmaceuticals, Inc REGN | $664.45 | $594.40 | -11% |
| Samsung Biologics Co 207940 | 1,368,000 KRW | 1,091,384 KRW | -20% |
| Celltrion, Inc 068270 | 175,800 KRW | 76,325 KRW | -57% |
| WuXi Biologics (Cayman) Inc 2269 | HK$39.54 | HK$30.42 | -23% |
| Innovent Biologics, Inc 1801 | HK$86.70 | HK$19.66 | -77% |
| Sino Biopharmaceutical Limited 1177 | HK$5.26 | HK$3.36 | -36% |
| ALTEOGEN Inc 196170 | 276,500 KRW | 44,444 KRW | -84% |
| RemeGen Co 688331 | ¥134.02 | ¥26.99 | -80% |
| Biocon Limited BIOCON | ₹440.70 | ₹57.36 | -87% |
Compare ADBiotech Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is ADBiotech Co (179530) overvalued or undervalued?
What is the fair value of 179530?
What is the quality score of 179530?
What is the revenue of ADBiotech Co (179530)?
What is the net profit margin of 179530?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track ADBiotech Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.